Bringing a new drug to market is tougher than marathon. For pharma startups, the main hurdles are regulatory and compliance barriers which has the power to even slow down the most promising innovations.

With global rules constantly shifting and approval processes stretching over years, it’s tough but not impossible to get therapies to patients faster. I believe startups can clear these obstacles by planning smartly and using practical tools.

This piece breaks down these strategies into bite-sized steps, backed by facts, to help startups turn regulatory puzzles into clear paths.

Step 1: Get "used to" with Regulators from the Start

The sooner startups talk to regulatory bodies like the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA), the better.

Waiting too long can lead to costly mistakes, because only 12% of drugs in clinical trials win FDA approval, obviously because companies didn’t align early with regulators.

The following are the ways to make them work:

  • Clarify the rules: Pre-submission meetings with the FDA or EMA help startups understand what’s expected, like specific safety data or trial designs. This avoids dead-end projects.
  • Fast-track options: Programs like the FDA’s Breakthrough Therapy designation can cut approval times by years for drugs tackling unmet needs. BioMarin Pharmaceutical used this to speed up its hemophilia gene therapy approval in 2023.
  • Build trust: Regulators are more likely to guide startups that show commitment to compliance early.

Startups should schedule these meetings as soon as they have a clear drug concept. It’s like getting a map before starting a hike, as it saves you from wandering off course.

Step 2: Use Tech to Tame the Paperwork Beast

Documentation is a massive time-suck in drug development, which takes 10-15 years and costs up to $4.2 billion. Messy paperwork can delay approvals, but technology can make it easier. Startups can use the following tools to stay organized and compliant:

  • eCTD software: Electronic Common Technical Document tools, like those from Veeva Systems, standardize submissions across regions, cutting errors. They’re affordable even for small teams.
  • Blockchain for trust: Blockchain creates secure, tamper-proof records for clinical data, which regulators love. IBM’s 2020 pilot with the FDA showed it can speed up reviews.
  • Cloud platforms: These keep all documents in one place, making audits smoother and ensuring compliance with International Council for Harmonization (ICH) guidelines.

By leaning on these tools, startups can focus on science instead of drowning in forms.

Step 3: Nail Your Clinical Data

Regulators won’t budge without solid proof that a drug is safe and effective. Poor trial data is a top reason for rejections, so startups need to get this right.

  • Follow Good Clinical Practice (GCP): These guidelines ensure trials are ethical and reliable. Moderna’s COVID-19 vaccine trials, with 30,000 participants, met FDA standards fast because they stuck to GCP.
  • Invest in data systems: Clean, accurate data prevents delays. Software like Medidata helps manage trial results.
  • Hire experts: Regulatory consultants can design trials that meet global standards, saving time and money.

Step 4: Navigate Global Rules with Local Help

Every country has its own regulatory quirks. The EMA’s centralized process is smoother than India’s CDSCO, which can add 2-3 years with tough inspections.

Startups can’t ignore these differences.

Partnering with consultants like Pharmatech Associates helps tailor strategies to specific markets without breaking the bank.

Lastly, regulatory barriers don’t have to stop pharma startups in their tracks. By building relationships with regulators, using tech to streamline work, nailing clinical data, and getting help with global rules, startups can move faster and smarter.

Edited by Harshajit Sarmah